Cytosorbents Schedules Key FDA Pre-Submission Meetings for DrugSorb-ATR Programs
CTSO sits 29% above its 52-week low of $0.37 on elevated volume (3.7× avg).
Summary
Cytosorbents announced it has scheduled two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs for DrugSorb-ATR, marking a key step in its regulatory path.
Key Events · Product Development and Regulatory · CTSO
-
FDA Pre-Submission Meetings Scheduled
Cytosorbents will hold two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs for DrugSorb-ATR.
-
Addressing Prior Regulatory Setbacks
One meeting will focus on generating additional mechanistic data required for a new De Novo submission for the ticagrelor program, following a prior denial.
-
Advancing DOAC Indication
A separate meeting will review existing data for the DOAC indication to determine requirements for a parallel De Novo submission, consistent with its Breakthrough Device Designation.
-
Critical for Future Growth
These steps are crucial for DrugSorb-ATR to gain potential U.S. and Canadian marketing approval, which is vital for the company's long-term growth and financial stability amidst ongoing challenges.
Analysis · CTSO · Industrial Applications And Services
Cytosorbents has scheduled two critical pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs for DrugSorb-ATR. These meetings are a vital step in addressing previous regulatory setbacks and advancing the company's investigational device towards potential U.S. marketing approval. Given the company's ongoing financial challenges, including a going concern warning and Nasdaq delisting risk, progress on its core product pipeline is essential for its long-term viability and growth.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTSO was trading at $0.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $29.3M. The 52-week trading range was $0.37 to $1.39. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.